Morpholine → HCID 44545389, compound

HRID 2093403Notes

Reaction equation

HRID 2093403 reaction equation
C(OC([NH:8][C:9]1[N:14]=[CH:13][C:12]([C:15]2[N:23]=[C:22]3[C:18]([N:19]=[CH:20][N:21]3[CH2:24][C:25]([OH:27])=O)=[C:17]([N:28]3[CH2:33][CH2:32][O:31][CH2:30][CH2:29]3)[N:16]=2)=[CH:11][N:10]=1)=O)(C)(C)C.[NH:34]1[CH2:39][CH2:38][O:37][CH2:36][CH2:35]1>>[NH2:8][C:9]1[N:10]=[CH:11][C:12]([C:15]2[N:23]=[C:22]3[C:18]([N:19]=[CH:20][N:21]3[CH2:24][C:25]([N:34]3[CH2:39][CH2:38][O:37][CH2:36][CH2:35]3)=[O:27])=[C:17]([N:28]3[CH2:29][CH2:30][O:31][CH2:32][CH2:33]3)[N:16]=2)=[CH:13][N:14]=1

Participants

3

Reactant 2

HCID 8083MorpholineHCID 58015218HCID 58015218, compound

Product 1

HCID 44545389HCID 44545389, compound

Procedure

2-(2-(2-(Tert-butoxycarbonylamino)pyrimidin-5-yl)-6-morpholino-9H-purin-9-yl)acetic acid (35 mg) was reacted with morpholine via General Procedure F followed by Boc deprotection via General Procedure E and purified via reverse phase HPLC to give 3.2 mg 124 as a white solid. MS (Q1) 426.2 (M)+

Workup

  1. custompurified via reverse phase HPLC

Sources & evidence

ORD record
ord-61c808bee7da4391ac052ade4f3cd947
Source dataset
uspto-grants-2013_05
Patent number
US08445487B2

Reaction notes

Loading…